THE RUSSIAN REGISTRY OF RITUXIMAB. ANALYSIS OF THE EFFICIENCY OF THERAPY AND THE FUNCTIONAL STATEOF PATIENTS WITH RHEUMATOID ARTHRITIS
Objective: To evaluate the functional status of patients with rheumatoid arthritis (RA) receiving two courses of rituximab (RTМ) therapy and its efficiency from the Russian registrys data. Subjects and methods. The analysis covered 269 patients receiving 1 or 2 courses of RT therapy, their clinical...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2010-08-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/1077 |
| _version_ | 1797862882130526208 |
|---|---|
| author | Vera Nikolayevna Amirdzhanova D V Goryachev G V Lukina K Kh Kuzikyants E L Nasonov |
| author_facet | Vera Nikolayevna Amirdzhanova D V Goryachev G V Lukina K Kh Kuzikyants E L Nasonov |
| author_sort | Vera Nikolayevna Amirdzhanova |
| collection | DOAJ |
| description | Objective: To evaluate the functional status of patients with rheumatoid arthritis (RA) receiving two courses of rituximab (RTМ) therapy and its efficiency from the Russian registrys data. Subjects and methods. The analysis covered 269 patients receiving 1 or 2 courses of RT therapy, their clinical follow-up schedules and quality of life (QL) questionnaires were filled in before drug administration and at 8, 16, and 24 weeks of a follow-up: 220 and 49 patients received 1 and 2 courses of RT therapy, respectively. The DAS28 index was used to evaluate disease activity; the patients functional status was assessed according to the Health Assessment Questionnaire (HAQ). Results. The patients' mean age was 46.5311.79 years; the disease duration was 9.806.87 years; disease activity scale (DAS28) scores were 6.501.06; the majority of patients had significant functional disorders estimated at 1.90 [1.37-2.38] scores according to the HAQ; 78% patients had extra-articular manifestations; rheumatoid factor was detected in 82.9%; the patients received more than 2 basic antiinflammatory drugs on average; 33.5% took TNF-р inhibitors. After the first course of therapy at 24 weeks of the follow-up, there was a gradual decline in DAS28 from 6.491.05 to 4.091.32 scores (p < 0.000001, ANOVA). A significant reduction in serum C-reactive protein was achieved during the first course of therapy just at 2 weeks of the follow-up. A decrease in DAS28 to і1.2 was seen in 79.9 of the patients after the first course at 24 weeks of the follow-up and in 85.7% after the second course. 13% of patients achieved drug-induced remission (DAS28 |
| first_indexed | 2024-04-09T22:26:42Z |
| format | Article |
| id | doaj.art-e2590599e64746449e8730dc8a9fea6d |
| institution | Directory Open Access Journal |
| issn | 1995-4484 1995-4492 |
| language | Russian |
| last_indexed | 2024-04-09T22:26:42Z |
| publishDate | 2010-08-01 |
| publisher | IMA PRESS LLC |
| record_format | Article |
| series | Научно-практическая ревматология |
| spelling | doaj.art-e2590599e64746449e8730dc8a9fea6d2023-03-22T13:45:45ZrusIMA PRESS LLCНаучно-практическая ревматология1995-44841995-44922010-08-01484314010.14412/1995-4484-2010-11631017THE RUSSIAN REGISTRY OF RITUXIMAB. ANALYSIS OF THE EFFICIENCY OF THERAPY AND THE FUNCTIONAL STATEOF PATIENTS WITH RHEUMATOID ARTHRITISVera Nikolayevna AmirdzhanovaD V GoryachevG V LukinaK Kh KuzikyantsE L NasonovObjective: To evaluate the functional status of patients with rheumatoid arthritis (RA) receiving two courses of rituximab (RTМ) therapy and its efficiency from the Russian registrys data. Subjects and methods. The analysis covered 269 patients receiving 1 or 2 courses of RT therapy, their clinical follow-up schedules and quality of life (QL) questionnaires were filled in before drug administration and at 8, 16, and 24 weeks of a follow-up: 220 and 49 patients received 1 and 2 courses of RT therapy, respectively. The DAS28 index was used to evaluate disease activity; the patients functional status was assessed according to the Health Assessment Questionnaire (HAQ). Results. The patients' mean age was 46.5311.79 years; the disease duration was 9.806.87 years; disease activity scale (DAS28) scores were 6.501.06; the majority of patients had significant functional disorders estimated at 1.90 [1.37-2.38] scores according to the HAQ; 78% patients had extra-articular manifestations; rheumatoid factor was detected in 82.9%; the patients received more than 2 basic antiinflammatory drugs on average; 33.5% took TNF-р inhibitors. After the first course of therapy at 24 weeks of the follow-up, there was a gradual decline in DAS28 from 6.491.05 to 4.091.32 scores (p < 0.000001, ANOVA). A significant reduction in serum C-reactive protein was achieved during the first course of therapy just at 2 weeks of the follow-up. A decrease in DAS28 to і1.2 was seen in 79.9 of the patients after the first course at 24 weeks of the follow-up and in 85.7% after the second course. 13% of patients achieved drug-induced remission (DAS28https://rsp.mediar-press.net/rsp/article/view/1077rituximabpatient functional statusregistry |
| spellingShingle | Vera Nikolayevna Amirdzhanova D V Goryachev G V Lukina K Kh Kuzikyants E L Nasonov THE RUSSIAN REGISTRY OF RITUXIMAB. ANALYSIS OF THE EFFICIENCY OF THERAPY AND THE FUNCTIONAL STATEOF PATIENTS WITH RHEUMATOID ARTHRITIS Научно-практическая ревматология rituximab patient functional status registry |
| title | THE RUSSIAN REGISTRY OF RITUXIMAB. ANALYSIS OF THE EFFICIENCY OF THERAPY AND THE FUNCTIONAL STATEOF PATIENTS WITH RHEUMATOID ARTHRITIS |
| title_full | THE RUSSIAN REGISTRY OF RITUXIMAB. ANALYSIS OF THE EFFICIENCY OF THERAPY AND THE FUNCTIONAL STATEOF PATIENTS WITH RHEUMATOID ARTHRITIS |
| title_fullStr | THE RUSSIAN REGISTRY OF RITUXIMAB. ANALYSIS OF THE EFFICIENCY OF THERAPY AND THE FUNCTIONAL STATEOF PATIENTS WITH RHEUMATOID ARTHRITIS |
| title_full_unstemmed | THE RUSSIAN REGISTRY OF RITUXIMAB. ANALYSIS OF THE EFFICIENCY OF THERAPY AND THE FUNCTIONAL STATEOF PATIENTS WITH RHEUMATOID ARTHRITIS |
| title_short | THE RUSSIAN REGISTRY OF RITUXIMAB. ANALYSIS OF THE EFFICIENCY OF THERAPY AND THE FUNCTIONAL STATEOF PATIENTS WITH RHEUMATOID ARTHRITIS |
| title_sort | russian registry of rituximab analysis of the efficiency of therapy and the functional stateof patients with rheumatoid arthritis |
| topic | rituximab patient functional status registry |
| url | https://rsp.mediar-press.net/rsp/article/view/1077 |
| work_keys_str_mv | AT veranikolayevnaamirdzhanova therussianregistryofrituximabanalysisoftheefficiencyoftherapyandthefunctionalstateofpatientswithrheumatoidarthritis AT dvgoryachev therussianregistryofrituximabanalysisoftheefficiencyoftherapyandthefunctionalstateofpatientswithrheumatoidarthritis AT gvlukina therussianregistryofrituximabanalysisoftheefficiencyoftherapyandthefunctionalstateofpatientswithrheumatoidarthritis AT kkhkuzikyants therussianregistryofrituximabanalysisoftheefficiencyoftherapyandthefunctionalstateofpatientswithrheumatoidarthritis AT elnasonov therussianregistryofrituximabanalysisoftheefficiencyoftherapyandthefunctionalstateofpatientswithrheumatoidarthritis AT veranikolayevnaamirdzhanova russianregistryofrituximabanalysisoftheefficiencyoftherapyandthefunctionalstateofpatientswithrheumatoidarthritis AT dvgoryachev russianregistryofrituximabanalysisoftheefficiencyoftherapyandthefunctionalstateofpatientswithrheumatoidarthritis AT gvlukina russianregistryofrituximabanalysisoftheefficiencyoftherapyandthefunctionalstateofpatientswithrheumatoidarthritis AT kkhkuzikyants russianregistryofrituximabanalysisoftheefficiencyoftherapyandthefunctionalstateofpatientswithrheumatoidarthritis AT elnasonov russianregistryofrituximabanalysisoftheefficiencyoftherapyandthefunctionalstateofpatientswithrheumatoidarthritis |